Post-stroke inflammation—target or tool for therapy?

KL Lambertsen, B Finsen, BH Clausen - Acta neuropathologica, 2019 - Springer
Inflammation is currently considered a prime target for the development of new stroke
therapies. In the acute phase of ischemic stroke, microglia are activated and then circulating …

TNF biology, pathogenic mechanisms and emerging therapeutic strategies

GD Kalliolias, LB Ivashkiv - Nature reviews rheumatology, 2016 - nature.com
TNF is a pleiotropic cytokine with important functions in homeostasis and disease
pathogenesis. Recent discoveries have provided insights into TNF biology that introduce …

The ClusPro web server for protein–protein docking

D Kozakov, DR Hall, B Xia, KA Porter, D Padhorny… - Nature protocols, 2017 - nature.com
Abstract The ClusPro server (https://cluspro. org) is a widely used tool for protein–protein
docking. The server provides a simple home page for basic use, requiring only two files in …

Nanobodies as therapeutics: big opportunities for small antibodies

S Steeland, RE Vandenbroucke, C Libert - Drug discovery today, 2016 - Elsevier
Highlights•Nanobodies (Nbs) are camelid-derived single-domain antibodies.•Nbs have
powerful binding and inhibitory capacity with great therapeutic potential.•Nbs are used in …

[HTML][HTML] TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects

L Probert - Neuroscience, 2015 - Elsevier
Tumor necrosis factor (TNF) is the prototypic pro-inflammatory cytokine. It is central to host
defense and inflammatory responses but under certain circumstances also triggers cell …

Selective targeting of TNF receptors as a novel therapeutic approach

R Fischer, RE Kontermann… - Frontiers in cell and …, 2020 - frontiersin.org
Tumor necrosis factor (TNF) is a central regulator of immunity. Due to its dominant pro-
inflammatory effects, drugs that neutralize TNF were developed and are clinically used to …

Immunogenicity and humanization of single‐domain antibodies

MA Rossotti, K Bélanger, KA Henry… - The FEBS Journal, 2022 - Wiley Online Library
Single‐domain antibodies (sdAbs), the autonomous variable domains of camelid and shark
heavy‐chain antibodies, have many desirable properties as components of biologic drugs …

TNF and TNF receptors as therapeutic targets for rheumatic diseases and beyond

D Siegmund, H Wajant - Nature Reviews Rheumatology, 2023 - nature.com
The cytokine TNF signals via two distinct receptors, TNF receptor 1 (TNFR1) and TNFR2,
and is a central mediator of various immune-mediated diseases. Indeed, TNF-neutralizing …

A new venue of TNF targeting

S Steeland, C Libert, RE Vandenbroucke - International journal of …, 2018 - mdpi.com
The first Food and Drug Administration-(FDA)-approved drugs were small, chemically-
manufactured and highly active molecules with possible off-target effects, followed by …

Principles of immunotherapy: implications for treatment strategies in cancer and infectious diseases

K Naran, T Nundalall, S Chetty, S Barth - Frontiers in microbiology, 2018 - frontiersin.org
The advances in cancer biology and pathogenesis during the past two decades, have
resulted in immunotherapeutic strategies that have revolutionized the treatment of …